Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | IL4 | P05112 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14315854 | 0.84 | KDM1A (0.47) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL17948458 | 0.83 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL27984907 | 0.82 | KMT2A (0.51) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL30701856 | 0.81 | GCGR (0.51) | GCGR | |
| SCHEMBL29185525 | 0.81 | GCGR (0.51) | GCGR | |
| SCHEMBL14315362 | 0.81 | ADORA1 (0.44) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL13118740 | 0.80 | GCGR (0.51) | GCGR | |
| SCHEMBL27984538 | 0.80 | ADORA1 (0.43) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL2340258 | 0.79 | GCGR (0.43) | GCGR | |
| SCHEMBL8208256 | 0.79 | GCGR (0.43) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135859-B | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-113135859-A | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2021-07-20 | — | — | CN | claimed |
| EP-3247703-B1 | IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR | CENTRIENT PHARMACEUTICALS NETHERLANDS B V (NL) | 2024-10-16 | — | — | EP | disclosed |
| CN-118063392-A | Improved process for preparing statin precursors | 灿盛制药有限公司荷兰公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-113135859-B | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-113135859-A | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-107428703-B | Improved process for the preparation of statin precursors | 灿盛制药有限公司荷兰公司 | 2021-01-12 | — | — | CN | disclosed |
| US-10246423-B2 | Process for preparing statin precursor | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2019-04-02 | — | — | US | disclosed |
| US-10246423-B2 | Process for preparing statin precursor | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2019-04-02 | — | — | US | disclosed |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-04-26 | — | — | US | disclosed |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-04-26 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| CN-104774183-A | Preparation method of formoxyl rosuvastatin calcium intermediate | HEFEI XINNUOHUA BIOTECHNOLOGY CO LTD | 2015-07-15 | — | — | CN | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| WO-2012172564-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | DR. REDDY'S LABORATORIES LIMITED (IN) | 2012-12-20 | — | — | WO | disclosed |
| CN-101323597-B | Preparation of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amido) pyrimidine-5-formaldehyde | ANHUI QINGYUN PHARMACEUTICAL AND CHEMICAL CO LTD | 2012-09-05 | — | — | CN | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
| CN-101323597-A | Preparation of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amido) pyrimidine-5-formaldehyde | ANHUI QINGYUN PHARMACEUTICAL A (CN) | 2008-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | ADORA1 2992/4885ADORA2A 3765/4885ADORA2B 3148/4885 |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | HMGCR, CYP11B1, OSBP | ADORA1 4463/4885ADORA2A 4551/4885ADORA2B 3834/4885 |
| US-10246423-B2 | Process for preparing statin precursor | HMGCR, STS, DHPS | ADORA1 4407/4885ADORA2A 4674/4885ADORA2B 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.